Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Accured Expenses (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Change in Accured Expenses for 10 consecutive years, with $584000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 126.36% to $584000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 255.06% year-over-year, with the annual reading at -$2.6 million for FY2025, 255.06% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was $584000.0 at Rein Therapeutics, up from -$34000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $1.8 million in Q2 2024, with the low at -$3.2 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is -$93900.0, with a median of $94000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses crashed 737.61% in 2022, then soared 473.24% in 2023.
  • Over 5 years, Change in Accured Expenses stood at -$226000.0 in 2021, then plummeted by 737.61% to -$1.9 million in 2022, then soared by 105.76% to $109000.0 in 2023, then soared by 136.7% to $258000.0 in 2024, then soared by 126.36% to $584000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $584000.0, -$34000.0, and -$3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.